Introduction 72 73
Exacerbations of asthma and wheeze are mostly triggered by respiratory viral infections and 74 are one of the most common reasons for a child to seek emergency care. 1 Previous studies 75 from our group have demonstrated that rhinovirus (RV) species C is the most frequent viral 76 pathogen detected in children who present to the local emergency department (ED) with an 77 asthma exacerbation. 2 However, the molecular mechanisms that determine susceptibility to 78 RV and expression of respiratory symptoms are not well understood. Previous investigations 79 of airway epithelial cells infected with RV in vitro found that type I and III interferon 80 responses were deficient in adults with asthma, leading to impaired viral control and 81 exaggerated secondary responses. 3, 4 However, this finding was replicated in some studies 82 but not others. 5 Human adult asthmatic volunteers experimentally infected with RV in vivo 83 have exaggerated IL-25 and IL-33 responses, which drive Th2 inflammation. 6, 7 Although 84 these data provide a plausible mechanism to link RV infection with the pathogenesis of 85 asthma, they are based on experimental models with artificial infections from laboratory RV 86 strains. Hence, the extent they can recreate the complex environmental conditions 87 underpinning natural RV-induced exacerbations is unclear. 1, 8 Indeed, studies of naturally 88 occurring virus-induced exacerbations report increased rather than decreased interferon 89 responses. [9] [10] [11] In this study, we have utilized an unbiased, systems biology approach to 90 elucidate the innate immune mechanisms that are operating in the upper airways during 91 natural exacerbations of asthma or wheezing in children. 9, 10 The study was based on a case/control design. The cases (n=56) consisted of children who 100 presented to the ED with an acute exacerbation of asthma or wheeze. The controls 101 consisted of children who were either siblings of the cases, or they were recruited from the 102 general community (controls, n=31) . Convalescent samples (n=19) were available from 103 children after they had recovered from an acute exacerbation of asthma or wheeze, but 104 only a subset of these convalescent samples (n=5/19) were paired with acute samples. 105
Samples from an independent group of children (n=99) with exacerbations of asthma or 106 wheeze were utilised as a replication cohort. The characteristics of the study participants 107 are presented in Table 1 . 108 109 Children with wheezing exacerbations were younger (mean = 4.35 (SD 3.31) years) than 110 controls (6.40 (SD 4.41) years, p = 0.025) and had fewer Caucasians (46.4% vs 78.6%, p = 111 0.006). A higher proportion of the children with wheezing exacerbations were sampled 112 during winter, compared to convalescence (p = 0.001) and controls (p = 0.028). Respiratory 113 virus, in particular, RV, was widely detected during wheezing exacerbations (87.0%, and 114 66.1%, respectively) compared with convalescence (42.1% and 26.3%, p < 0.001 and p = 115 0.003, respectively) and controls (58.1% and 32.3%, p = 0.004 and p = 0.003, respectively). 116 RV-C was more prevalent during wheezing exacerbations (46.4%) compared with controls 117 (12.9%, p = 0.002). The number of viruses detected during acute exacerbations (1.13 (SD 118 0.76) was higher than during convalescence (0.47 (SD 0.61), p = 0.001). No difference in 119 bacterial detection was observed between the groups. 120
121
The proportion of children with wheezing exacerbations recruited in winter in the 122 replication cohort was lower than the discovery cohort (p < 0.001, Table 1 ). The replication 123 cohort was also more atopic (78.8% vs 60.7%, p = 0.024), and had lower detection rates of 124 respiratory viral and bacterial pathogens compared to the latter. Respiratory symptoms, 125 hospital admissions and medication usage were not different in the discovery and 126 replication cohorts. 127 128 Gene expression profiling of exacerbation responses in the upper airways 129 130 Nasal swab specimens were collected from the children and gene expression patterns were 131 profiled on microarrays. Cellular composition data of the samples was not available, and 132 therefore a computational approach was employed to estimate the proportions of different 133 cell types directly from the microarray profiles. 31 As illustrated in Figure 1a , the highest 134 proportions were observed for neutrophils, epithelial cells, and monocytes. Stratification of 135 the subjects by case/control status and RV detection revealed that wheezing exacerbations 136 were associated with increased proportions of M1 macrophages and decreased proportions 137 of conventional dendritic cells (Figure 1b ). The proportions of the other cell types were 138 mostly comparable across the groups. The relationship between case/control status, RV 139 detection and cellular composition for each individual child is illustrated in Figure 1c . 140 141 To identify differentially expressed genes, we undertook group-wise comparisons employing 142 LIMMA in combination with Surrogate Variable Analysis, which adjusts the analysis for all 143 estimated sources of unwanted biological and technical variation (See Methods). 144
Comparison of gene expression patterns between children with RV positive wheezing 145 exacerbations (n=37) versus RV negative controls (n=21) revealed that 137 genes were 146 upregulated and 82 genes were downregulated (adjusted p-value < 0.05, Table S1 ). 147 Pathways analysis demonstrated that the upregulated genes were highly enriched for type I 148 interferon signalling (adjusted p-value = 4.8 x 10 -22 , relevant genes are highlighted in Table  149 S1). Type I interferon signalling (adjusted p-value = 8.5 x 10 -31 , Table S2 ) was also 150 upregulated in children with RV positive exacerbations in comparison to RV negative 151 convalescent children (n=14). 152 153 Gene expression patterns were then assessed in children with RV negative exacerbations. 154
Comparison of these children (n=19) with RV negative controls (n=21) revealed that 17 155 genes were upregulated and 10 genes were downregulated (adjusted p-value < 0.05, Table  156 S3). Similar results were obtained by comparing children with RV negative exacerbations 157 versus RV negative convalescent children (n=14), where 30 differentially expressed genes 158 were identified (adjusted p-value < 0.05, Table S4 ). While a subset of these genes were also 159 upregulated in children with RV positive exacerbations (e.g. IL-18R1, CD163), a notable 160 difference was the lack of an interferon signature. 161
162
Discovery of molecular sub-phenotypes of acute wheezing illnesses 163
164
The findings above suggested that children with RV positive exacerbations mount an 165 interferon response but there appears to be additional heterogeneity. As the data analysis 166 strategy relied on group-wise comparisons (with LIMMA/SVA), this approach cannot shed 167 any insight into subject-to-subject variations in gene expression patterns within each group. 168
To obtain more detailed information in this regard, we employed hierarchical clustering (See 169 Methods). To ensure that the clustering did not simply reflect variations in cellular 170 composition (observed above in Figure 1 ), we utilised a set of negative control genes (i.e. 171
genes not related to the outcome of interest) to model unwanted variation in the data, and 172 removed these effects using regression (See Methods and Figure S1 ). This strategy 173 preserves the gene expression signature associated with acute exacerbations in the data, 174 and removes the strong correlation structure between samples that reflect variations in 175 cellular composition ( Figure S1 ). As illustrated in Figure 2a , cluster analysis of the corrected 176 data divided the subjects into five distinct clusters or molecular phenotypes (labelled S1-S5). 177
Likewise, the genes were also divided into five clusters labelled G1-G5. Notably, the majority 178 of children with exacerbations (45/56 = 80%) were found within clusters S1 and S2, and 179 there was no difference in RV detection between these cluster groups of children (RV 180 detection rates for children with exacerbations in cluster S1 vs cluster S2 were 73% vs 58%, 181 p-value = 0.347). The other three clusters S3-S5 contained the bulk of the controls and the 182 convalescent samples, as well as 11 remaining children with exacerbations. 183
184
To examine the overall expression of each gene cluster across the children, principal 185 component analysis was employed to summarise the expression data for each cluster, and 186 the first principal component was plotted across the subjects, stratified into their respective 187 clusters. This analysis revealed that the most striking difference between the subjects in 188 cluster groups S1 and S2 was the differential expression of the set of genes in cluster G5 189 ( Figure 2b ), and this cluster of genes was strongly enriched for type I interferon signalling 190 (data not shown). Moreover, prior knowledge based reconstruction of the wiring diagram of 191 the underlying gene networks for each cluster revealed that IRF7 -a master regulator of 192 type I interferon responses, 32 was the dominant hub gene identified in cluster G5. 193 Accordingly, we designated the children in clusters S1 and S2 as IRF7 hi versus IRF7 lo 194 molecular phenotypes. 195 196 Network hubs and driver genes underlying IRF7 hi versus IRF7 lo molecular phenotypes 197 198 To further characterize the IRF7 phenotypes, children with exacerbations were stratified 199 into IRF7 hi (n=26) and IRF7 lo (n=19) subgroups, and compared with RV negative controls 200 employing LIMMA/SVA. We followed this strategy because a direct comparison of IRF7 hi/low 201 phenotypes would only reveal differences between the respective responses, and we 202 wanted to know if the phenotypes operate through discrete and/or overlapping pathways. 203
The data showed that 208 genes were upregulated and 157 genes were downregulated in 204 children with IRF7 hi exacerbations compared with controls ( Figure 3a , left panel; Table S5 ). 205 IRF7 lo exacerbations were characterized by upregulation of 96 genes, and downregulation of 206 31 genes downregulated (Figure 3a , right panel; Table S6 ). These analyses revealed an 207 overlapping response signature, which comprised 52 upregulated genes and 11 208 downregulated genes. Gene network analysis revealed that IRF7 gene networks were 209 upregulated in the children with IRF7 hi exacerbations (Figure 3b , left panel). IRF7 lo 210 exacerbations lacked an IRF7 signature, and instead were characterized by upregulation of 211 Th2-associated pathways (e.g. IL-4R, FCER1G, ARG1) and downregulation of IFNg (Figure 3b , 212 right panel). We also built a combined network to illustrate the unique and overlapping 213 gene network patterns for each phenotype (Figure 4) . 214 215 Next we employed upstream regulator analysis to identify molecular drivers of IRF7 hi and 216 IRF7 lo exacerbation responses. 28, 33 The data showed that IRF7 hi exacerbations were 217 putatively driven by upregulation of IFNL1, IRF7, and interferon alpha signalling (Figure 3c , 218 left panel, Table S7 ). In contrast, IRF7 lo exacerbations were predicted to be driven by 219 upregulation of cytokine and growth factor signalling pathways (e.g. IL-6, IL-10, TGFb, ERK, 220 CSF3, EGF, Figure 3c , right panel, Table S8 ). It is noteworthy that multiple inflammatory 221 pathways (e.g. IL-1b, IL-2, IL-4, IL-13, TNF, OSM, IFNG) featured in the upstream regulator 222 analysis results for IRF7 lo exacerbations, however the activation Z-scores were not 223 significant, indicating that the direction of the gene expression changes in terms of up-and 224 down-regulation were not consistent with the known role of these pathways in the 225 regulation of gene expression. 28 226
227
We re-examined the cellular composition data from Figure 1 in IRF7 hi and IRF7 lo 228 exacerbation responses, and we found that both phenotypes were associated with 229 decreased proportions of cDCs, and similar proportions of M1 macrophages ( Figure S2 ). 230 To identify candidate pathways that potentially link exacerbation responses with expression 237 of asthma-related traits, we employed Pubmatrix 34 to screen the literature for relevant 238 studies (Table S9 ). We found that multiple genes which were upregulated in children with 239 IRF7 hi exacerbations (e.g. CASP1, CD274, CXCL11, DDX58, Haptoglobin, IFIH1, IRF7, P2RX7, 240 PHF11, Selectin L, SERPING1, STAT1, TLR4, TLR5, TNFAIP3, TNFAIP6, TNFSF13B) or IRF7 lo 241 exacerbations (e.g. AGR3, C3AR1, EPCAM, IL4R, LDLR, NCR1, OCLN, SERPINB2, SERPINB3, 242 THBS1, TIMP1, VCAN) have been previously studied in the context of asthma and/or related 243 traits. Moreover, overlap signature of genes that were commonly upregulated in children 244 with IRF7 hi and IRF7 lo exacerbations have also been previously studied in this context (e.g. 245 ADAM17, ARG1, ARG2, CD163, CD38, FCER1G, IL18R1, PLA2G4A, S100A12, TLR2). 246
247
Clinical characteristics of IRF7 hi versus IRF7 lo exacerbations 248 249 We next investigated the biological and clinical characteristics of IRF7 hi and IRF7 lo 250 exacerbations. These groups were not related to any technical variables measured in the 251 study (Table S10 ). There was also no difference in season of recruitment, the detection of 252 viral or bacterial pathogens, or the use of medications ( Table 2 ). The prevalence of atopy, 253 including allergy to aeroallergens, was higher in IRF7 hi exacerbations (76.9% and 73.1%, 254 respectively) compared with IRF7 lo exacerbations (42.1% and 31.6%, p = 0.029 and 0.008, 255 respectively). Children with IRF7 lo exacerbations presented to hospital much later after 256 initial symptoms (4.74 (SD 4.03) days) than IRF7 hi exacerbations (2.31 (SD 1.98) days, p = 257 0.011). This was also reflected in the duration of cough prior to hospitalization (IRF7 lo : 5.62 258 (SD 3.20) days and IRF7 hi : 1.96 (SD 1.51) days, respectively, p = 0.000027). Children with 259 IRF7 lo exacerbations were at least 4.6 times more likely to be admitted to hospital compared 260 with IRF7 hi exacerbations (OR 4.65, p = 0.018). Time to subsequent first 261 representation/admission to hospital with an exacerbation was shorter in IRF7 lo 262 exacerbations compared with IRF7 hi exacerbations (Table 2, Fig S5) . Within the first year of 263 follow-up, more children with IRF7 lo (68.4%) represented/readmitted to hospital with a 264 respiratory exacerbation compared to those with IRF7 hi (30.8%, p = 0.017). All associations 265 remained significant after adjustment for age, gender, aeroallergen allergy and Caucasian Figure 4 ), or that were common to both 277 phenotypes (ARG1, CD163, FCER1G, IL-1R2, IL-18R1, TLR2, Figure 4 ). The RT-qPCR data was 278 normalised to three endogenous control genes (HMBS, PPIA, PPIB), creating three separate 279 variables for each gene, which were utilised for consensus clustering. The analysis 280 segregated the subjects into five clusters ( Figure 5 ); three of these had elevated expression 281 of IRF7/interferon responses (combined as IRF7 hi ; black dendrogram in Figure 5 ), and the 282 remaining two clusters had low IRF7/interferon responses (IRF7 low1 and IRF7 low2 ; red and 283 green dendrograms respectively in Figure 5 ). A longer time lag was observed from first 284 symptoms to hospital presentation in the IRF7 low1 subjects (3.90 (SD 4.59) days) compared 285 with the IRF7 hi group (2.20 (SD 1.76) days, p = 0.023). These symptoms included cough 286 (p=0.015), wheeze (p=0.022) and shortness of breath (p = 0.02). Fever was more prevalent 287 in the IRF7 hi group (59.2%) compared with the IRF7 low1 and IRF7 low2 groups (24.1%, p = 0.004 288 and 10.0%, p < 0.001, respectively). Runny nose was also more prevalent in the IRF7 hi group 289 (75.5%) compared to the IRF7 low2 group (45.0%, p = 0.024). All associations remained 290 significant after adjusting for age, gender, aeroallergy and Caucasian ethnicity. 291 292 293
Discussion 294 295 Our study is the first to investigate acute wheeze/asthma exacerbation phenotypes in 296 children using a systems biology approach. We have confirmed the central role of IRF7 as a 297 gene network hub and have identified two distinct IRF7 molecular phenotypes, IRF7 hi 298 exhibiting robust upregulation of the Th1/type I interferon response and IRF7 lo with an 299 alternative activation signature marked by upregulation of cytokine and growth factor 300 signalling and downregulation of interferon gamma. Importantly, the two phenotypes also 301 produced distinct clinical phenotypes. Compared with children with IRF7 hi , those with IRF7 lo 302 had a slower progression of illness from initial symptoms to hospital presentation, a greater 303 likelihood of a hospital admission, and a greater chance of representation with a further 304 exacerbation. Exacerbation severity at presentation was not different between the two IRF7 305 patterns, perhaps because presentation to hospital is likely to be determined by symptoms 306 reaching a severity threshold that causes parental concern. However also worth noting is 307 that the apparently impaired IRF7 response in IRF7 lo children was not associated with an 308 increase in exacerbation severity at presentation, although perhaps expectedly the reduced 309 IRF7 response was associated with slower resolution of the episode. These findings were 310 unaffected by the respiratory viruses or bacteria detected and medication use. Investigation 311 of a replication cohort using RT-qPCR produced similar findings despite variations in the 312 subject characteristics between the discovery and replication cohorts. In summary our 313 findings reveal two distinct phenotypes with clear differences in gene regulation patterns, 314 either upregulation of robust innate immune responses or cytokine and growth factor 315 signalling, and associated differences in clinical characteristics. 316 317 Asthma and wheezing exacerbations are largely triggered by RV infections but the 318 underlying mechanisms are not well understood. 2 Previous in vitro studies suggested that 319 RV-induced interferon responses were deficient in bronchial epithelial cells from subjects 320 with asthma, resulting in increased viral loads and exaggerated secondary responses. 3, 4, 35 321 However, in vivo studies of immune response patterns in the airways of both children and 322 adults with RV-induced exacerbations found that interferon responses were increased, not 323 deficient. [9] [10] [11] 36 Moreover, a clinical trial that evaluated the utility of inhaled interferon beta 324 therapy in adults at the first signs of a cold to prevent worsening of their asthma symptoms 325 failed to achieve its primary endpoint. 37 Our data extend these previous findings by 326 demonstrating that wheezing exacerbations in children are heterogeneous and 327 characterised by two very different IRF7 molecular phenotypes. Upstream regulator analysis 328 suggested that IRF7 hi exacerbations were driven by upregulation of IFNL1, IRF7, and 329 interferon alpha signalling. In contrast, IRF7 lo exacerbations were putatively driven by 330 upregulation of cytokine and growth factor signalling (i.e. IL-6, IL-10, TGFb, CSF3, EGF) and 331 downregulation of interferon gamma. 332 333 IRF7 is a master regulator of type I and type III interferon gene expression. 32, [38] [39] [40] We 334 previously reported that IRF7 gene networks were upregulated in nasal wash samples from 335 asthmatic children experiencing mild-to-moderate viral exacerbations. 10 We have also 336 shown that IRF7 promotes RV-induced innate antiviral responses and limits IL-33 mRNA 337 expression in cultured bronchial epithelial cells, 33 and furthermore in our current study IL-33 338 was downregulated in IRF7 hi exacerbation responses. Girkin et al. reported that knockdown 339 of IRF7 abolished RV-induced type I interferon responses in the airways in a mouse model. 40 340
Together, these experimental findings support our computational analysis unveiling IRF7 as 341 a regulator of the gene networks underlying the IRF7 hi responder phenotype. 342 343 Children with IRF7 lo exacerbations in the discovery cohort exhibited a delayed progression 344 from first symptom onset to hospital presentation. Given that our study design entailed 345 recruitment of children at ED presentation, we could not determine if IRF7 gene networks 346 were initially upregulated closer to the onset of infection and subsequently waned, or 347 alternatively if they were never upregulated in the first place. To address this issue, an 348 alternative study design would be required which entails regular sampling of exacerbation-349 prone children during the RV season. 41 It would also be of interest to further study the 350 stability of these identified phenotypes to learn if subjects experience the same type of 351 response over multiple wheezing exacerbation events or not. Notwithstanding this, our 352 replication cohort comprised approximately twice as many cases as the discovery cohort, 353 and this larger sample enabled the identification and characterization of two subgroups of 354 IRF7 lo children, and only one of these subgroups was characterized by delayed progression. 355
The activation of growth factor signalling pathways and downregulation of interferon 356 gamma may reflect the immune response entering a resolution phase, however, at the 357 same time these children were symptomatic. Moreover, many were also RV positive, and 358
given that TGFb signalling promotes rhinovirus replication, upregulation of this pathway 359 may prolong infection and delay viral clearance. 42, 43 It is also known that frequent severe 360 exacerbations are associated with deficits in lung function growth (children) and accelerated 361 lung function decline (adults). 44 Thus repeated cycles of inflammation, growth factor 362 signalling and repair may alter the structure and function of the airways underlying this 363 phenotype. 364
365
The mechanisms that determine expression of disease symptoms amongst children with 366 IRF7 hi and IRF7 lo exacerbations are unknown. Given that children with IRF7 hi exacerbations 367 elicit robust antiviral responses, one possibility is that the airways of these children are 368 sensitive to the host response to respiratory viruses. In this regard, several pathways 369 associated with the IRF7 hi phenotype are known to impact on respiratory function. PD-L1 370 (encoded by CD274) is an immune checkpoint that delivers an inhibitory signal for T cell 371 activation. Upregulation of PD-L1 during respiratory bacterial infections in early life 372 suppresses the IL-13 decoy receptor IL-13Ra2, resulting in persistent airways 373 hyperresponsiveness. 45 MDA5 (encoded by IFIH1) is a pattern recognition receptor that 374 senses RV-derived RNA. MDA5 deficient mice infected with RV have delayed type I 375 interferon responses, impaired type III interferon responses, and reduced airways 376 hyperresponsiveness. 46 The proinflammatory effectors TNF, IFNg, and interferon gamma-377 induced protein 10 can also promote airway hyper-responsiveness in animal models. 47-49 378 379 Another possibility is that IRF7 hi and IRF7 lo exacerbation responses converge on a final 380 common pathway to precipitate respiratory symptoms ( Figure 4 ). For example, CD38 is a 381 receptor with enzymatic activity, which hydrolyses NAD, generating reaction products that 382 modulate calcium signalling. It is expressed on immune and airway smooth muscle cells, and 383 it plays a dual role in asthma by enhancing airways inflammation and contractile responses 384 in smooth muscle. 50 FCER1G is a component of the high affinity IgE receptor. Anti-IgE 385 therapy neutralises serum IgE, reduces the expression of the high affinity IgE receptor on 386 dendritic cells and mast cells, and it also reduces the frequency of asthma exacerbations. 51, 387 52 Phospholipases A2 are involved in the generation of eicosanoids from arachidonic acid. 388
Knock-in of human sPLA2 into mice enhances airways inflammation and airways 389 hyperresponsiveness. 53 TLR2 is a pattern recognition receptor that acts as a sensor for RV 390 capsid. 54 In a mouse model of combined RV and allergen exposure, TLR2 signaling in 391 macrophages was required for induction of airways inflammation and airways 392 hyperresponsiveness. 55 In summary, our data has identified multiple candidate pathways 393 that link IRF7 hi and IRF7 lo exacerbation responses with expression of respiratory symptoms, 394 and these pathways represent logical candidates for future drug development programs. 395
396
This study has limitations that should be acknowledged. The expression profiles were 397 derived from nasal swab samples that comprised a mixed cell population. Follow-up studies 398 employing focused analyses in individually isolated cell types or single cell transcriptomics 399 will be required to dissect the role of specific subpopulations of cells in this disease. The 400 study participants were sampled during natural exacerbations, and it is not possible to 401 control for all of the variables that may potentially impact on the data (e.g. age, gender, 402 ethnicity, natural allergen exposure, pathogen strains and combinations, medications). To 403 address this issue, our analysis strategy employed surrogate variable analysis to 404 systematically estimate and adjust the analysis for all sources of hidden biological and/or 405 technical variation. Some of the clinical characteristics associated with IRF7 phenotypes in 406 the discovery cohort did not replicate in the validation cohort. This may be due in part to 407 variations in the demographics and clinical characteristics between the two cohorts, as well 408 as the fact that IRF7 phenotypes were defined in the discovery cohort by microarray analysis 409 of a large number of genes, whereas in the validation cohort it was based on RT-qPCR 410 analysis of a restricted gene panel. Finally, while our analyses have characterised gene 411 network patterns underlying exacerbation phenotypes and unveiled candidate molecular 412 drivers of the responses, further studies will be required to dissect the mechanisms that give 413 rise to these phenotypes and drive the expression of respiratory symptoms. 414
Notwithstanding these limitations, our findings demonstrate that exacerbation responses in 415 children are heterogeneous and comprise IRF7 hi versus IRF7 lo molecular phenotypes that 416 determine clinical phenotypes. Future clinical trials targeting the interferon system in this 417 disease should be stratified on the basis of these IRF7 phenotypes. We thank all the children and their families who agreed to take part in the study. The participants were part of an ongoing study examining the mechanisms of acute viral 659 respiratory infection in children (MAVRIC) . Cases were children aged 0-16 years presenting 660 to the ED of a tertiary children's hospital (Princess Margaret Hospital, Perth, Western 661 Australia) with acute wheeze and the availability of nasal fluid and swab specimens. All 662 respiratory diagnoses were determined by the treating physician and were independent of 663 study staff. Controls consisted of siblings of the cases or randomly selected children from 664 the community. We defined 'admission to hospital' as admission to a non-ED hospital ward. 665
We also collected 19 convalescent/quiescent nasal samples from children who were 666 followed-up at least 6 weeks after an acute exacerbation of asthma or wheeze; only a 667 subset of these samples (5/19) were paired with acute samples. The hospital's Human Ethics 668
Committee approved the study (MAVRIC approval 1761 EP) and parental/guardian written 669 informed consent was obtained prior to recruitment. An independent sample of children 670 from within the MAVRIC cohort was used as a validation cohort. 671 672
Data and sample collection 673
A detailed questionnaire and medical records were used to provide demographic and 674 medical information for each participant during recruitment and follow-up. A child was 675 considered positive for aeroallergy if they had a positive response to either (1) the skin prick 676 test completed on 9 allergens (rye grass, mixed grasses, dog, cat, cockroach, Alternaria 677 tenuis, Aspergillus fumigatus, Dermatophagoides farinae, D. pteronyssinus), or (2) a positive 678 specific IgE to either cat or house dust mite (>0.35kU/L) at either the acute or convalescent 679 visit, or positive answers to the acute questionnaire for the questions "Does your child 680 suffer from hayfever?", or "Does your child suffer from allergies to: (a) grasses/pollens?; or 681 (b) dust mite?". A child was considered positive for allergy overall if they had (1) aeroallergy; 682 or (2) a positive response to the skin prick tests for either cows' milk or egg white, or (3) a 683 parental report of a history of anaphylaxis, or (4) a high total IgE at either the acute or 684 convalescent visit. 685 686 Acute asthma severity scores were assigned to each child at recruitment using a modified 687 National Institute of Health score for children over 2 years of age 12 and included 688 assessments of respiratory rate appropriate for age, oxygen saturation, auscultation, 689 retractions and dyspnea. A separate, age-appropriate severity score was used for children 690 aged under 2 years 13 with assessments of heart rate, respiratory rate, wheezing and 691 accessory muscle use. Separate severity Z scores were calculated for each child within each 692 of the two age groups to provide standardized scores across the whole cohort. 693
694
The time to next re-presentation or admission to a public hospital in Western Australian 695 with any acute respiratory illness for each child, within the first and second year of 696 observation, was obtained from the state hospital database retrospectively. 697 698 A nasal secretion sample from each participant was collected to test for the presence of 699 respiratory viruses and bacteria. Nasal swab specimens were obtained from each child using 700 flocked swabs (Copan, Italy) and were taken immediately to the laboratory for processing 701 for gene expression profiling. Streptococcus Pneumoniae and pyogenes) were identified using a tandem multiplex real-709 time PCR assay as previously described. 14 Rhinovirus (RV) was detected and genotyped by a 710 molecular method as previously described. 15, 16 711 712
Microarray analysis of gene expression 713
Total RNA was extracted from nasal swabs using TRIzol (Invitrogen) followed by RNeasy 714 MinElute (QIAgen). 10 The quality and integrity of the RNA was analysed on the nanodrop 715 and bioanalyzer (Agilent). Total RNA samples were shipped on dry ice to the Ramaciotti 716 Centre for Genomics, at the University of New South Wales, Sydney, for processing and 717 hybridization to Human Gene 2.1 ST microarrays (Affymetrix). The raw microarray data are 718 available from the gene expression omnibus repository (accession: GSE103166). 719 720
Microarray data analysis 721
The microarray data was preprocessed in R employing the Robust Multi-Array (RMA) 722 algorithm. 17 A custom chip description file (hugene21sthsentrezg; version 20) was utilized to 723 map probe sets to genes. 18 The quality of the microarray data was assessed employing the R 724 package arrayQualityMetrics. Low quality/outlying arrays were identified on the basis of 725 Relative Log Expression (RLE) and Normalized Unscaled Standard Error (NUSE) metrics and 726 removed from the analysis. 19, 20 Differentially expressed genes were identified using Linear 727 Models for Microarray Data (LIMMA) in conjunction with Surrogate Variable Analysis 728 (SVA). 21, 22 Limma entails fitting a linear model to the log expression intensities for each 729 gene, and Empirical Bayes methods are employed to moderate the standard error estimates 730 resulting in improved power and more stable inference. 21 Surrogate Variable Analysis 731 estimates and captures all sources of hidden biological and/or technical variation that may 732 potentially confound the analysis, and the estimated surrogate variables are added as 733 covariates to the limma models. Where applicable, the correlation between paired samples 734 was accounted for in the linear model fit through use of the duplicateCorrelation function. 735 P-values derived from the limma models were adjusted for multiple testing employing the 736 false discovery rate method. 21 Non-informative probe sets were identified using the 737 proportion of variation accounted by the first principal component (PVAC) algorithm and 738 filtered out of the results from the differential expression analysis. 23 739 740
Discovery of molecular phenotypes 741
Molecular phenotypes were identified using consensus hierarchical clustering. 24 This 742 algorithm employs data resampling techniques to find consensus across thousands of runs 743 of a cluster analysis. 24 Prior to cluster analysis, batch-like effects and other sources of 744 unwanted variation were modelled and removed using the RUVnormalize algorithm. 25 This 745 algorithm leverages a set of negative control genes that are not associated with the 746 outcome of interest to model unwanted variation and regress it out of the data. To select 747 negative control genes, genes associated with wheezing exacerbations were first identified 748 in case/control comparisons between wheezing/convalescent or wheezing/control samples 749 using LIMMA/SVA, and those genes with an adjusted p-value less than 0.2 for any 750 comparison were excluded from control gene selection. Negative control genes (n=1000) 751 were selected from the remaining genes using the empNegativeControls function from the 752 RUVCorr package. 26 After removal of unwanted variation using the RUVnormalize algorithm, 753 the gene expression data was converted to Z-scores, and consensus hierarchical clustering 754 was performed using the set of genes that were associated with the outcome of interest 755 (adjusted p-value < 0.1). Hierarchical cluster analysis was performed using Pearson 756 correlation and ward linkage. 757 758
Pathways analysis 759
Pathways analysis was performed using Enrichr software and the Reactome database. 27 760 761
Prior knowledge based reconstruction of gene networks 762 Gene networks were constructed employing experimentally supported findings from 763 published studies curated in the Ingenuity Systems Knowledge Base (Ingenuity Systems, 764
Redwood City, California). Direct and indirect molecular relationships were considered from 765 all available categories, including activation, inhibition, localisation, modification, molecular 766 cleavage, phosphorylation, protein-DNA interaction, protein-protein interaction, regulation 767 of binding, transcription, translation, and ubiquitination. The circular layout was employed 768 to display the network graph object, and hubs were positioned at the centre of the network. 769
The nodes were coloured based on the expression ratio; red nodes denote upregulated 770 genes and green nodes denote downregulation. 771 772
Upstream regulator analysis 773
Upstream regulator analysis (Ingenuity Systems, Redwood City, California) was employed to 774 infer the molecular drivers of the observed differential gene expression patterns. 28 Two 775 statistical metrics were calculated. The overlap p-value measures enrichment of known 776 downstream target genes for a given upstream regulator amongst the differentially 777 expressed genes. The activation Z-score is a measure of the pattern match between the 778 direction of the observed gene expression changes (in terms of up/down regulation) and the 779 predicted pattern based on prior experimental evidence. Pathways with an activation Z-780 score greater than 2.0 are predicted to be activated, and an activation Z-score less than -2.0 781 indicates pathway inhibition. If the activation Z-score lies between -2.0 and 2.0, the 782 activation state of the pathway cannot be predicted. Comparisons of all categorical variables between the clusters were performed using χ 2 test 808 while ANOVA was used for continuous variables. Kaplan-Meier survival curve was used to 809 assess the time to first re-presentation or admission after recruitment. A p-value of less 810 than 0.05 was considered significant. All analyses were performed using SPSS version 22 811 (Chicago, Illinois). 812 813 Meier curve of the proportion of children that have a subsequent hospital 849 presentation/admission for any respiratory diagnosis followed for a maximum of 3.55 years. 850 Censored data represents the length of time a child was followed and did not have another 851 hospital presentation/admission for a respiratory illness. 852 853 Table S1 : Differential gene expression in children with RV positive exacerbations vs RV 854 negative controls. 855 Table S2 : Differential gene expression in children with RV positive exacerbations vs RV 856 negative convalescence. 857 Table S3 : Differential gene expression in children with RV negative exacerbations vs RV 858 negative controls. 859 
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